Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKKMarkus Borner, Walter Mingrone, Dieter Koeberle et al.|Annals of Oncology|2008Cited by 129
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Martin Bigler, Roger von Moos et al.|BMC Cancer|2016Cited by 46
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.Christoph Rochlitz, Ralph C. Winterhalder, Roger von Moos et al.|Journal of Clinical Oncology|2014Cited by 14
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer—Further observations from the IMPACT solid studyJohanna Mäenpää, Shailendra Verma, Ioannis Varthalitis et al.|The Breast|2015Cited by 10
Editorial BoardChristoph Thomssen, Karl-Friedrich Bürrig, Norbert Marschner et al.|Breast Care|2012Cited by 0